4Lloyd-Jones D, O' Donnell C, D' Agostino R, et al. Applicability of cholesterol-lowering primary prevention trials to a general population: the framingham heart study. Arch Intern Med, 2001,161(7) :949-954.
5Welty F. Cardiovascular disease and dyslipidemia in women. Arch Intern Med, 2001, 161 (4) :514 - 522.
6Bruckert E. Prevention of cardiovascular events in elderly hypercholesterolemic patients. Curr Atheroscler Rep, 1999,1(1) :9-15.
7Brown W. The benefit of aggressive lipid lowerinu. Atheroscler Suppl, 2000,1 ( 1 ):15- 19.
8Latts L M. Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans. Am J Med,2001, 110(suppl 6A) : 17S- 23S.
9Yasunari K, Maeda K, Minami M, et al. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vase Biol, 2001,21(6) :937-942.
10Barter P. Treating to target with statins Atheroseler Suppl, 2000,1 ( 1 ) : 21 - 25.
